Shire PLC (ADR)  

(Public, NASDAQ:SHPG)   Watch this stock  
Find more results for Shire US, Inc
218.39
-2.49 (-1.13%)
Real-time:   3:18PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 215.44 - 218.57
52 week 136.68 - 264.98
Open 216.46
Vol / Avg. 698,597.00/1.02M
Mkt cap 43.24B
P/E 20.38
Div/yield 0.11/0.29
EPS 10.71
Shares 597.50M
Beta 0.65
Inst. own 9%
Feb 11, 2015
Q4 2014 Shire PLC Earnings Release (Estimated) - 3:00AM EST - Add to calendar
Dec 10, 2014
Shire PLC Research and Development Day
Nov 12, 2014
Shire PLC at Credit Suisse Healthcare Conference
Oct 24, 2014
Q3 2014 Shire PLC Earnings Call
Oct 24, 2014
Q3 2014 Shire Plc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 32.21% 28.69%
Operating margin 35.81% 35.13%
EBITD margin - 40.09%
Return on average assets 18.03% 18.10%
Return on average equity 32.69% 30.94%
Employees 5,338 -
CDP Score - 83 C

Address

Citywest Business Campus 5 Riverwalk, Dublin 24
DUBLIN,
Ireland
+353-1-4297700 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Shire plc (Shire) is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), gastrointestinal (GI) diseases, human genetic therapies (HGT) and regenerative medicine (RM), as well as opportunities in other therapeutic areas. On January 31, 2012, the United States Food and Drug Administration approved VYVANSE for the maintenance treatment of ADHD in adults. In March 2013, it announced the acquisition Of Premacure AB. In January 2014, Shire Plc sold its DERMAGRAFT assets to Organogenesis Inc. In January 2014, Shire Plc acquired 79.5% interest in ViroPharma Inc. Effective May 12, 2014, the Company acquired Lumena Pharmaceuticals Inc.

Officers and directors

F. Ornskov M.D. Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
James Bowling Interim Chief Financial Officer
Age: 45
Bio & Compensation  - Reuters
Tatjana May General Counsel, Company Secretary
Age: 47
Bio & Compensation  - Reuters
Susan S Kilsby Non-Executive Chairman of the Board
Age: 55
Bio & Compensation  - Reuters
David J. Kappler Senior Independent Non-Executive Deputy Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Dominic Blakemore Non-Executive Director
Age: 44
Bio & Compensation  - Reuters
William Burns Non-Executive Independent Director
Age: 66
Bio & Compensation  - Reuters
Steven H. Gillis Ph.D. Non-Executive Independent Director
Age: 50
Bio & Compensation  - Reuters